Similar articles

• The disparity of pharmacokinetics and prolactin study for risperidone long-acting injection.

  Peng PW, Huang MC, Tsai CJ, Pan CH, Chen CC, Chiu CC. Peng PW, et al. J Clin Psychopharmacol. 2008 Dec;28(6):726-7; author reply 727-8. doi: 10.1097/JCP.0b013e31818d7ca2. J Clin Psychopharmacol. 2008. PMID: 19011459 Clinical Trial. No abstract available.
• Prolactin serum levels in paranoid versus nonparanoid male schizophrenia patients treated with risperidone.

  Segal M, Avital A, Derevenski A, Berstein S, Sandbank S, Weizman A. Segal M, et al. Int Clin Psychopharmacol. 2007 Jul;22(4):192-6. doi: 10.1097/YIC.0b013e3280803f3b. Int Clin Psychopharmacol. 2007. PMID: 17519641 Clinical Trial.
• Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics.

  Bushe C, Shaw M. Bushe C, et al. J Psychopharmacol. 2007 Sep;21(7):768-73. doi: 10.1177/0269881107078281. Epub 2007 Jul 2. J Psychopharmacol. 2007. PMID: 17606473
• Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.

  Keith S. Keith S. Expert Rev Neurother. 2009 Jan;9(1):9-31. doi: 10.1586/14737175.9.1.9. Expert Rev Neurother. 2009. PMID: 19102665 Review.
• [The first long-acting atypical antipsychotic: new milestone in the treatment of schizophrenia].

  Faludi G. Faludi G. Neuropsychopharmacol Hung. 2005 Mar;7(1):22-7. Neuropsychopharmacol Hung. 2005. PMID: 16167464 Review. Hungarian.